AttendMe Owl Logo
AttendMe
Evidence Evolution
Critical CareCritical Care

How This Evidence Evolved

ICU Glucose Control

The pendulum swings

4.5

Timeline

Signal

Early observations and pilot data that first suggested a new direction

Leuven I randomized 1,548 mechanically ventilated surgical ICU patients to intensive insulin therapy targeting 80–110 mg/dL or conventional treatment. ICU mortality was 4.6% with intensive therapy versus 8.0% with conventional treatment. Overall in-hospital mortality was reduced by 34%. Intensive therapy also reduced bloodstream infections, dialysis-requiring renal failure, and critical-illness polyneuropathy. These findings prompted further testing of glucose targets in other ICU populations.
Proof

Landmark RCTs and pivotal trials that established the evidence base

Leuven II evaluated intensive insulin therapy in 1,200 medical ICU patients. In the intention-to-treat analysis, in-hospital mortality was 37.3% with intensive therapy versus 40.0% with conventional therapy (P=0.33). Intensive treatment reduced morbidity, including newly acquired kidney injury, and hastened weaning and discharge. Mortality differed by length of ICU stay, but the relevant subgroups could not be identified before treatment. Further studies were needed to establish the balance of benefit and harm.
Extension

Follow-up studies, subgroup analyses, and real-world validation

NICE-SUGAR randomized 6,104 ICU patients to a glucose target of 81–108 mg/dL or 180 mg/dL or less. Mortality at 90 days was higher with intensive control (27.5% versus 24.9%; OR 1.14; 95% CI 1.02–1.28). Severe hypoglycaemia, defined as glucose 40 mg/dL or less, occurred in 6.8% versus 0.5%. There were no significant differences in ICU stay, hospital stay, ventilation duration, or renal replacement duration. The trial established that the lower glucose target increased mortality in this broad ICU population.
Guidelines

Integration into clinical practice guidelines and recommendations

SSC 2021 recommends initiating insulin at glucose ≥180 mg/dL in adults with sepsis or septic shock (strong recommendation), with a typical subsequent target of 144–180 mg/dL. It attributes lower-target concerns chiefly to hypoglycemia risk. The SSC recommendation is not the older rule requiring two consecutive readings above 180 mg/dL.
Surviving Sepsis Campaign 2021

For adults with sepsis or septic shock, initiate insulin at glucose ≥180 mg/dL (strong recommendation); typical target after initiation 144–180 mg/dL.

Now

Current standard of care and ongoing research directions

SSC describes a typical 144–180 mg/dL target after insulin initiation in sepsis. Glycemic variability is associated with short-term mortality, but an association does not establish benefit from targeting variability itself. Monitoring technologies have also been tested: a small sepsis RCT found better dysglycemia detection with CGM, and a 24-patient trial demonstrated feasibility of automated closed-loop control. TGC-Fast, which withheld early parenteral nutrition, found no difference in ICU-care duration or 90-day mortality with algorithm-guided tight control. CONTROLING tested HbA1c-derived individualized targets versus glucose below 180 mg/dL and found no survival benefit; it stopped early for low benefit likelihood and possible hypoglycemic harm. These completed trials test different strategies.

Landmark Trials in This Story

New England journal of medicine 2001Landmark

Intensive insulin therapy in critically ill patients

ICU mortality 4.6% vs 8.0%, p<0.04

New England journal of medicineRCTN=1,548
New England journal of medicine 2006Landmark

Intensive insulin therapy in the medical ICU

Hospital mortality: intensive 37.3% vs conventional 40.0% (P=.33); morbidity benefit with ICU stay≥3 days

New England journal of medicineRCTN=1,200
Glucontrol2009

A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study

Stopped early for protocol violations; ICU death: IIT 17.2% vs intermediate 15.3%; hypoglycaemia 8.7% vs 2.7%

Intensive Care MedRCTN=1,101
NICE-SUGAR2009Landmark

Intensive versus conventional glucose control in critically ill patients

90-day mortality 27.5% vs 24.9%, OR 1.14 (95% CI 1.02–1.28), p=0.02

New England journal of medicineRCTN=6,104
Diabetes Ther 2025

In-Hospital Management of Hyperglycemia: The Role of Insulin Degludec.

Narrative review reports ADA 2025 ICU glucose targets and selected surgical-patient exceptions; not an ICU insulin-degludec trial.

Diabetes TherNarrative review
TGC-Fast2023

Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU.

ICU discharge alive with tight vs liberal glucose control: HR 1.00, 95% CI 0.96–1.04; P=.94

The New England journal of medicineRandomized controlled trialN=9,230
CONTROLING2021

Individualised versus conventional glucose control in critically-ill patients: the CONTROLING study-a randomized clinical trial.

Survival at 90 days: individualized 67.2% vs conventional 69.6% (95% CIs 64.2–70.3 and 66.7–72.5)

Intensive care medicineMulticentre randomized double-blind trialN=2,075
Closed-loop ICU feasibility2013

Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial.

Time in 6–8 mmol/L target over 48 hours: closed-loop 54.3% vs local protocol 18.5% (P=.001)

Critical care (London, England)Prospective randomized controlled trialN=24
CGM sepsis trial2026

Clinical validation of continuous glucose monitoring in glycemic management of critically ill sepsis patients: A prospective randomized clinical study.

Time in target during ICU monitoring: CGM 33.23% vs conventional 26.26%

The Journal of international medical researchProspective randomized clinical trialN=60
Glycemic variability meta-analysis2024

Glycemic Variability As a Prognostic Factor for Mortality in Patients With Critical Illness: A Systematic Review and Meta-Analysis.

Association of glucose-variability metrics with short-term mortality; abstract omits pooled effect estimates

Critical care explorationsSystematic review and meta-analysis of 41 studiesN=162,259

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

Why do ICU glucose-control trial results differ?+
The trials studied different populations and strategies. Leuven I enrolled mechanically ventilated surgical-ICU patients and compared 80–110 mg/dL with a conventional 180–200 mg/dL target. NICE-SUGAR found higher 90-day mortality and more severe hypoglycemia with 81–108 mg/dL versus ≤180 mg/dL in a broad ICU population. TGC-Fast notes nutrition and hypoglycemia as possible explanations for inconsistent trial results; it does not prove the cause of Leuven’s result.
What is the optimal glucose target in the ICU?+
SSC 2021 describes 144–180 mg/dL after insulin initiation in sepsis; it reports ADA guidance targeting 140–180 mg/dL. Avoid hypoglycaemia (<70 mg/dL). A 2025 review reports ADA 2025 targets of 110–140 mg/dL for selected critically ill surgical patients if achievable without significant hypoglycemia.
Does glycaemic variability matter?+
A systematic review of 41 studies involving 162,259 patients found a consistent association between greater glycemic variability and higher short-term mortality. The certainty varied by metric. This supports prognostic interest but does not establish that a variability-reduction treatment improves survival independently of other glucose-management effects.
What role does continuous glucose monitoring play in the ICU?+
A sepsis RCT of 60 patients found CGM feasible and detected more hypoglycemic events, with shorter measurement times. A separate 24-patient critical-illness RCT tested automated closed-loop insulin and dextrose delivery: time in the 6–8 mmol/L target was 54.3% versus 18.5% with a local sliding-scale protocol, without hypoglycemia in either group. These limited studies do not establish safety and accuracy across all ICU populations.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026